clinical trial · NCT07681440
A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
Bristol-Myers Squibb·—·terminated·n = 30
Myelodysplastic SyndromesBeta-thalassemiaLuspatercept
brief summary
The purpose of this study is to understand the patient profile, utilized treatments, treatment patterns, resulting outcomes, and associated costs relating to luspatercept treatment in patients with lower-risk myelodysplastic syndromes (LR-MDS) or beta-thalassemia in the real-world setting
started
Nov 16, 2023
primary completion
May 1, 2025
completion
May 1, 2025
last updated
Jul 2, 2026
official title
Real World Use of Luspatercept in Lower Risk Myelodysplastic Syndromes and Beta-thalassemia Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol